Trade Idea: IDXG

7/27/17

IDXG, our new trade idea has released news this morning that may be an additional catalyst for upside.

Interpace Diagnostics Announces Cigna Coverage of ThyGenX®

PARSIPPANY, N.J., July 27, 2017 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that Cigna, one of the largest national health plans in the United States, has agreed to cover Interpace’s ThyGenX® test for Cigna’s 15 million members nationwide, with coverage effective immediatelyCigna’s coverage combined with Aetna, United Healthcare, Medicare, and other payers brings the total number of covered lives for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules to approximately 275 million patients nationwide.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades. Most physicians have traditionally recommended thyroid surgery where thyroid nodule biopsy results are indeterminate, not clearly benign or malignant following traditional cytopathology review; however, over 70% of these surgical outcomes are ultimately benign.  Molecular testing using ThyGenX has been shown to reduce the rate of unnecessary surgeries in indeterminate cases.

Jack E. Stover, President and CEO of Interpace Diagnostics stated, “Cigna’s coverage of ThyGenX represents further acceptance among major health plans of our molecular products for Thyroid cancer.  We are pleased that Cigna has joined the growing list of health plans that cover ThyGenX and that their 15 million members will now have access to its benefits.”  

Source: Press Release


7/26/17

Our previous trade idea began trading around 0.98 following our alert and rallied to a high of 1.10 a few days later for upside potential of 12%. The trade opportunity did not break above its 20 day moving average to provide even more upside opportunity.

Today I would like to bring to your attention a new trade idea, one that I believe may potentially provide you with increased upside.

Trade Idea: Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)

Highlights:

  • IDXG rallied above its 20 day moving average a few days ago, rallying from 0.88 to a high of 1.06.
  • Today IDXG has retraced some of this upside, currently trading around 0.96.
  • In the event that IDXG is able to sustain its 20 day moving average of 0.90, this could provide you with increased upside opportunity.
  • IDXG has a RSI of 56, suggesting potential for further upside opportunity.
  • IDXG has a 50 day moving average of 1.35, 42% above current levels. This increased divergence signals the potential for increased volatility.

About IDXG:

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management.

The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.

Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Recent News:

Interpace Diagnostics Announces National Contract with Aetna

PARSIPPANY, N.J., June 28, 2017 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management announced today that it has signed a new national contract with Aetna for its ThyGenX ®and ThyraMIR® molecular tests for indeterminate thyroid nodules.

Aetna is the third largest health plan in the United States, with over 44.9 million members nationwide. The agreement covers many of Aetna’s products, including commercial and Medicare Advantage plans. It does not include Medicaid, auto insurance, or workman’s compensation products. The agreement goes into effect August 15, 2017. Aetna began covering ThyGenX in June 2015 and ThyraMIR in November 2016. 

The agreement is the Company’s first national provider contract with a national health plan and means that Interpace will now be part of Aetna’s laboratory network for these services.

“The agreement with Aetna is another significant reimbursement milestone demonstrating our ability to convert our product coverage approvals with major insurance providers into successful contractual agreements,” said Jack E. Stover, Interpace’s President and CEO, “Coverage of our thyroid products has continued to increase and improve over the past few quarters and now totals over 250 million covered lives.”

Source: Yahoo Finance

You need to evaluate the chart in real-time and establish for yourself whether it is an appropriate trade opportunity for you or not.​​​​​​​

If you are not familiar with my trading guidelines, please read them below.

These trading guidelines are designed to give you a starting point to develop your own personal trading philosophy and approach.

Since every traders/investors circumstance is different, make sure you create a personalized approach that works for you and always consult a financial adviser (not me).

Happy Trading!

Ultimate Stock Alerts 

—————————————————

Trading Rules [Please Review Before Taking Any Action]:

  1. Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb – if you cannot sleep at night as a consequence of your investment, then you have over invested.
  2. Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
  3. Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use “trailing stop %” or “trailing stop limit” orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
  4. Cut losses quickly when day/swing trading. It’s better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
  5. Actively manage all your investments & trade during market hours only. Trading during pre/post market hours carries greater volatility/risk.

DISCLAIMER

This report/release is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our reports/releases unless you can afford to lose your entire investment. The track record, gains, upside or losses are all hypothetical and should not be considered as a basis for investment.

This report/release is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reports/releases distributed through disseminated reports/released are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov;the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in our disseminated reports/releases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated report/release or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned herein.

We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.

The purpose of this report/release, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of UltimateStockAlerts.com have been compensated thirty five thousand dollars cash via bankwire, earned upon receipt, for distribution of our opinions and publicly available information for IDXG from World Wide Holdings on 07/14/17. Owners and operators of UltimateStockAlerts.com do not own any equity nor debt in IDXG as of 7/27/17. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated reports/releases does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Owners and operators of UltimateStockAlerts.com own several newsletters, therefore you may receive our emails featuring companies at different times.

You are receiving this report/release because you subscribed to received it at our website or through a third party site.  All of our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@ultimatestockalerts.com to change your information at any time.  By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer which can be read at any time at www.UltimateStockAlerts.com/Disclaimer.

Full disclaimer can be read at www.UltimateStockAlerts.com/Disclaimer.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

Leave a Reply

Your email address will not be published. Required fields are marked *

bonus

Free Guide To Become A Successful Trader/Investor

lock We Never Sell Or Share Your Email

No Hidden Fees. Unsubscribe Anytime.